Last quarter (Q2 2024), Anebulo Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Anebulo Pharmaceuticals's net income was $-2.72M. See Anebulo Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Jun 23	Jun 22	Jun 21	Jun 20
Total Revenue	-	-	-	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
Operating Expense	$ 10.66M	$ 11.78M	$ 6.83M	$ 3.61M	$ 173.35K
Operating Income	$ -10.66M	$ -11.78M	$ -6.83M	$ -3.61M	$ -173.35K
Net Non Operating Interest Income Expense	$ 115.77K	$ 92.41K	$ 7.33K	$ -10.75K	$ -1.29K
Other Income Expense	$ -55.06K	$ 41.15K	$ 1.78K	$ -26.63M	-
Pretax Income	$ -10.49M	$ -11.73M	$ -6.83M	$ -30.25M	$ -174.64K
Tax Provision	-	-	-	-	$ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-
Net Income Common Stockholders	$ -10.49M	$ -11.73M	$ -6.83M	$ -38.46M	$ -174.64K
Basic EPS	$ 0.52	$ 0.47	$ -0.29	$ -2.83	$ >-0.01
Diluted EPS	$ 0.52	$ 0.47	$ -0.29	$ -2.83	$ >-0.01
Basic Average Shares	$ 102.13M	$ 25.07M	$ 23.34M	$ 13.61M	$ 23.27M
Diluted Average Shares	$ 102.13M	$ 25.07M	$ 23.34M	$ 13.61M	$ 23.27M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	$ 10.66M	$ 11.78M	$ -6.83M	$ 3.61M	$ 173.35K
Net Income From Continuing And Discontinued Operation	$ -10.51M	$ -11.73M	$ -6.83M	$ -30.25M	$ -174.64K
Normalized Income	$ -10.60M	$ -9.27M	-	$ -3.63M	$ -174.64K
Interest Expense	-	-	-	$ 11.77K	$ 1.29K
EBIT	$ -10.46M	$ -11.73M	$ -6.83M	$ -30.24M	$ -173.35K
EBITDA	$ -10.43M	$ -11.73M	$ -6.83M	$ -30.24M	$ -173.35K

Currency in USD

Anebulo Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing